

Connecting patients everywhere to precision oncology

OncoPrint Dx Express Test (CE-IVD)

A patient's tumor profile has the potential to guide precision oncology care, but optimal treatment decisions rely on timely results.^{1,2}

Now, with the Ion Torrent™ OncoPrint™ Dx Express Test on the Genexus™ Dx System, you can perform fast next-generation sequencing (NGS) testing for clinically relevant biomarkers in as little as 24 hours. This specimen-to-report solution is easy to implement and operate with minimal hands-on time and offers industry-leading low sample input requirements. The proven amplicon-based technology allows ~95% sample success rates.³

If your lab routinely tests patient samples for oncology biomarkers, the OncoPrint Dx Express Test will enable you to:

- Easily integrate NGS into your laboratory workflow.** With automated library preparation, sequencing, analysis, and reporting involving 20 minutes of hands-on time and a single *in vitro* diagnostic (IVD) software, the OncoPrint Dx Express Test reduces laboratory staff burden and the potential for human errors, and alleviates the need for specialized bioinformatics expertise.
- Detect clinically relevant gene targets recommended by professional guidelines for multiple solid tumors.¹** The OncoPrint Dx Express Test detects substitutions, insertions and deletions, copy number variants (CNVs), and fusions and splicing variants across 46 genes, including *ALK*, *BRAF*, *EGFR*, *ERBB2*, *KRAS*, *MET*, *NTRK1/2/3*, *RET*, and *ROS1*, among others.
- Generate results in as little as 24 hours.** This enables the integration of molecular and immunohistochemistry (IHC) results into one complete report to aid clinicians in making timely therapy decisions.
- Help ensure that more patients receive genomic insights.** Requiring only 10 ng of DNA and RNA extracted from as little as two 5-micron formalin-fixed paraffin-embedded (FFPE) slides, results can be generated from limited tissue and small biopsies. Plasma from liquid biopsy provides an additional sample type.

Table 1. The OncoPrint Dx Express Test gene list.

DNA					RNA				
Deletions, insertions, and substitutions					Copy number alterations				
AKT1	ERBB2	IDH1	MAP2K2	PIK3CA	AR	FGFR2	ALK	NTRK1	
AKT2	ERBB3	IDH2	MET	PEN	EGFR	FGFR3	AR	NTRK2	
AKT3	ERBB4	KEAP1	NRAS	RAF1	ERBB2	KRAS	BRAF	NTRK3	
ALK	ESR1	KIT	NTRK1	RET	ERBB3	MET	ESR1	NUTM1	
AR	FGFR1	KRAS	NTRK2	ROS1	FGFR1	PIK3CA	FGFR1	RET	
ARAF	FGFR2	MAP2K1	NTRK3	STK11	EGFR		FGFR2	ROS1	
BRAF	FGFR3		PDGFRA	TP53	ERBB3		FGFR3	RSP02	
CDK4	FGFR4				FGFR1		MET	RSP03	
CHEK2	FLT3						NRG1		
CTNNB1	GNAS								
EGFR	HRAS								

Genes in bold are only available for FFPE.

The OncoPrint Dx Express Test covers 100% of clinical routine biomarkers in non-small cell lung cancer (NSCLC) and the majority of clinical routine biomarkers for other solid tumors according to ESMO: Tier 1 scale for clinical actionability of molecular targets^{1,4} (Table 1).

The Genexus Dx System automates the NGS workflow from patient sample to reporting and delivers results in as little as 24 hours with just two user touchpoints.*

With automated library preparation, sequencing, and analysis from 20 minutes of hands-on time, the OncoPrint Dx Express Test reduces laboratory staff burden and the potential for human error (Figure 1). One intuitive IVD software facilitates tracking sample information through the workflow. Analysis is performed automatically on-instrument, and local reporting alleviates the need for specialized bioinformatics expertise.

OncoPrint Dx Express Test Other NGS technologies





 Time to report	1 day	4–5 days
 Hands-on time	20 minutes	>10 hours
 Sample input	10 ng	40 ng

Figure 1. Comparison of NGS workflows.



* Timing varies by number of samples and sample type.

Elevate oncology care for your patients by implementing easy NGS biomarker testing today.

References

1. Mosele F, et al. (2020) *Ann Oncol* 31:1491.
2. Smeltzer M, et al. (2020) *J Thorac Oncol* 15:1434.
3. Volckmar AL, et al. (2019) *Int J Cancer* 145:649.
4. Mateo J, et al. (2018) *Ann Oncol* 29:1895.

Learn more at thermofisher.com/oncoPrint-dxexpress

For In Vitro Diagnostic Use. CE-IVD according to IVDD. Not available in all countries including the United States.

The content provided therein may relate to products that have not been officially released and is subject to change without notice.

© 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **EXT1752 0922**